Mycophenolate mofetil versus prednisone for the initial treatment of idiopathic steroid-sensitive nephrotic syndrome in children in Germany (INTENT): a multicentre, open-label, randomised, controlled, parallel-group, non-inferiority, phase 3 trial / Marcus R. Benz, Anja Sander, Rasmus Ehren, Britta Höcker, Alexander Fichtner, Jutta Gellermann, Julia Thumfart, Brigitte Mayer, Katja Sauerstein, Anne Mühlig, Raphael Schild, Nele Kanzelmeyer, Dieter Haffner, Henry Fehrenbach, Martin Pohl, Günter Klaus, Silke C. Schmidt, Martin Konrad, Uwe Querfeld, Peter F. Hoyer, Jörg Dötsch, Markus J. Kemper, Alexandra Balzer, Jan Meis, Burkhard Tönshoff, Lutz T. Weber

Related documents

• Efficacy and Safety of Rituximab to That of Calcineurin Inhibitors in Children With Steroid Resistant Nephrotic Syndrome#846425
• A Study to Assess Safety, Efficacy, and Pharmacokinetics of INM004 in Pediatric Patients With STEC-HUS#217147
• Randomized, Controlled, Open-label, Multicenter, Safety and Efficacy Study of rhHNS Administration Via an IDDD in Pediatric Patients With Early Stage MPS IIIA Disease#915132
• 21 U.S.C. § 393a — Office of Pediatric Therapeutics#577188
• Oral Tacrolimus vs Dexamethasone Micro-pulse Therapy in Pediatric Rapidly Progressing Vitiligo: A Multicenter RCT#1010742